ISRG is a $140B company that posted its first revenue in 1999 and went public in 2000 at a mkt cap of $300 million. It is the behemoth of robotic surgery today. During its first 10 years, the stock was incredibly volatile, trading at anywhere from 3x to 20x revenues.
PRCT went public in 2021 with $34.5 million of revenues, ending the year at a $1B mkt cap. It is also a robotic surgery company, currently with only one machine for prostate surgery. For 2028, estimated revenues are $475 million. The company is current trading at a $1.1B valuation, or 2.3x those revenues.
I have charted PRCT's revenue path against ISRG's from the comparable period of the giant's revenue lifecycle. The numbers with \* are the estimates for PRCT the next 2 years. The base year for ISRG is 2000. The base year for PRCT is 2021.
ISRG turned profitable in 2004 on $138 million of revenues. PRCT is not expected to be profitable until 2029 when sales are estimated at $650 million.